CoLucid reports positive results from Phase II study of migraine drug
The randomized, double-blind study evaluated 130 migraine patients. Patients were not on prophylaxis and received 2.5 to 45mg of COL-144 or placebo as an intravenous infusion over 20
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.